WO2018178608A1 - Methods of treatment of diabetic ulcers with microrna - Google Patents

Methods of treatment of diabetic ulcers with microrna Download PDF

Info

Publication number
WO2018178608A1
WO2018178608A1 PCT/GB2017/050923 GB2017050923W WO2018178608A1 WO 2018178608 A1 WO2018178608 A1 WO 2018178608A1 GB 2017050923 W GB2017050923 W GB 2017050923W WO 2018178608 A1 WO2018178608 A1 WO 2018178608A1
Authority
WO
WIPO (PCT)
Prior art keywords
ulcer
microrna
mature microrna
diabetic
precursors
Prior art date
Application number
PCT/GB2017/050923
Other languages
English (en)
French (fr)
Inventor
Sergiu-Bogdan CATRINA
Xiaowei ZHENG
Original Assignee
Catrina Sergiu Bogdan
Zheng Xiaowei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catrina Sergiu Bogdan, Zheng Xiaowei filed Critical Catrina Sergiu Bogdan
Priority to PCT/GB2017/050923 priority Critical patent/WO2018178608A1/en
Priority to CN201780089103.1A priority patent/CN110494146A/zh
Publication of WO2018178608A1 publication Critical patent/WO2018178608A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs

Definitions

  • the present invention relates to novel methods of treatment of ulcers in diabetic patients comprising administration of microRNAs or vectors encoding the same.
  • the invention relates to the use of microRNA-210 and precursors thereof, including in methods of treating and/or promoting the healing of diabetic ulcers.
  • Diabetes mellitus refers to a group of diseases in which the malfunction of glucose homeostasis results in hyperglycaemia experienced over a prolonged period.
  • the major subtypes of diabetes are type 1 (or insulin-dependent diabetes) and type 2 (insulin- independent diabetes).
  • Patients with diabetes are at high risk of developing skin ulcers.
  • the areas at greatest risk are the legs; particularly the feet.
  • the peripheral neuropathy that often develops as a result of chronic hyperglycaemia causes a loss of coordination of muscle groups in the feet and legs, which increases mechanical stresses during ambulation, increasing the likelihood of the formation ulcers on the lower legs or feet.
  • the sensation of pain is also reduced in extremities affected by peripheral neuropathy, further increasing the likelihood of ulcer formation due to the patient's lack of ability to identify the need to take preventative measures.
  • vascular disease developing in later stage diabetes may also contribute to lesion formation.
  • Diabetic ulcers and particularly diabetic foot ulcers are therefore one of the gravest complications of diabetes. Indeed, diabetic foot ulcers are responsible for more hospitalizations than any other complication of diabetes. Diabetes is the leading cause of non-traumatic lower extremity amputations in the United States, with approximately 5% of diabetics developing foot ulcers each year and 1 % requiring amputation. At present, there are no effective treatments for diabetic foot ulcers approved for use. Therefore, there exists a significant and unmet need for such treatments.
  • the inventors have now surprisingly found that the administration of mature microRNA- 210, or precursors thereto can improve the healing of diabetic ulcers in a patient in need thereof.
  • Methods of medical treatment
  • a method of treatment of an ulcer in a patient having diabetes comprising administering a therapeutically-effective amount of a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 to a patient in need of such treatment.
  • nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 for use in the treatment of an ulcer in a patient having diabetes.
  • nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 for the manufacture of a medicament for the treatment an ulcer in a patient having diabetes.
  • mature microRNA-210 (for example for use in various species such as mouse and human (e.g. human)) comprises or consists of (e.g. consists of) the nucleotide sequence CUGUGCGUGUGACAGCGGCUGA (SEQ ID NO: 1)
  • microRNA-210 may refer to mature microRNA-210, pre- microRNA-210 and/or primary-microRNA-210 (pri-microRNA-210), which terms will be understood by those skilled in the art.
  • the nucleic acids of the invention include mature microRNA-210 and precursors thereto.
  • suitable precursors include biological precursors, such as nucleic acids that may be processed into mature microRNA-210 by means of one or more cellular processing steps and/or result in the formation of mature microRNA-210 following their addition to a cell.
  • Such precursors include pri-microRNA-210, pre-microRNA-210, double-stranded mimics of mature microRNA-210, and vectors encoding microRNA-210.
  • the nucleic acid is a double-stranded mimic of mature microRNA- 210.
  • pri-microRNA-210 and pre-microRNA-210 are upstream precursors to mature microRNA-210.
  • pri-microRNA-210 may be understood to refer to the primary transcript(s) produced by the action of RNA polymerase II on the gene encoding microRNA-210
  • pre-microRNA- 210 may be understood to refer to the hairpin precursor(s) to mature microRNA-210 produced following the processing of pri-microRNA-210 by ribonuclease Ill-type enzyme Drosha.
  • Both pri-microRNA-210 and pre-microRNA-210 comprise, within longer nucleotide sequences, the nucleotide sequence of mature microRNA-210 (CUGUGCGUGUGACAGCGGCUGA (SEQ ID NO: 1)).
  • Double-stranded mimics of mature microRNA-210 include artificial double-stranded oligonucleotides designed to mimic the function of endogenous mature miRNA-210. Such mimics may be structurally similar to the double-stranded RNA produced following cleavage of the pre-microRNA-210 hairpin by Dicer ribonuclease and, therefore, may be loaded into RNA-induced silencing complex (RISC) and processed into single-stranded mature microRNA-210.
  • RISC RNA-induced silencing complex
  • An example of a suitable double-stranded mimic of microRNA- 210 is the miRIDIAN miR-210 mimic (miRIDIAN mmu-miR-210-3p; Cat #: C-310570-05, Dharmacon)
  • vectors are recombinant nucleic acid constructs that are engineered to express polynucleotides in target cells.
  • Vectors typically include the nucleic acid sequence encoding the polynucleotide to be expressed and one or more regulatory (or control) sequences that facilitate efficient transcription of that polynucleotide.
  • regulatory (or control) sequences that facilitate efficient transcription of that polynucleotide.
  • examples of vectors include plasmids, viral, and non-viral vectors, and the like.
  • vectors encoding microRNA-210 may be understood to be nucleic acid molecules comprising a polynucleotide sequence encoding microRNA-210 (pri-microRNA- 210, pre-microRNA-210 or mature microRNA-210 (e.g. pri-microRNA-210)), and optionally one or more regulatory sequences.
  • the vectors are DNA molecules comprising a polynucleotide sequence encoding microRNA-210 (pri-microRNA-210, pre- microRNA-210 or mature microRNA-210 (e.g. pri-microRNA-210)), and optionally one or more regulatory sequences.
  • Such vectors may be readily prepared using methods known to the person skilled in the art (such as, for example, those described in Green and Sambrook Molecular Cloning: A Laboratory Manual, Fourth Edition Coldspring Harbour Laboratory Press (2012) the contents of which is incorporated herein in its entirety).
  • mature microRNA-210 comprises or consists of (e.g. consists of) the nucleotide sequence CUGUGCGUGUGACAGCGGCUGA (SEQ ID NO: 1).
  • analogues of the nucleic acids of the invention may be used, as long as the mature microRNA administered or produced following the administration of precursors thereto maintains the ability to regulate its target(s).
  • Such analogues encompass miRNA sequences in which one or more bases are substituted or deleted.
  • the 'seed' sequence which is a sequence completely complementary to a sequence within the mRNA targeted by microRNA-210, should remain unchanged.
  • an analogue has at least about 75% identity or complementarity to mature microRNA-210; for example, at least about 80%, at least about 85%, at least about 90%, at least about 99% identity or complementarity to mature microRNA-210.
  • each possibility represents a separate embodiment of the present invention.
  • the terms may refer to achieving a reduction in the severity of one or more clinical symptom associated with the condition. For example, in the case of ulcers in patients having diabetes (i.e.
  • diabetic ulcers this may refer to promoting the healing of the ulcer such that the ulcer heals (i.e the skin or mucous membrane (e.g. skin) heals over) within an improved time frame relative to an untreated ulcer.
  • This time frame may be in the range of three to twelve months (for example six to twelve months).
  • this time frame may be three months
  • for ischemic diabetic ulcers the time frame may be six months.
  • a successful treatment may comprise achieving a measurable decrease in the size (e.g. width, depth, volume etc) of the ulcer within a certain time frame (for example within one month, such as within three months, e.g. within six months).
  • the size of the ulcer may be reduced by at least 10%; for example, at least 20%, such as at least 50% (e.g. at least 75%).
  • references to patients will refer to a living subject being treated, including mammalian (e.g. human) patients.
  • the treatment is in a mammal (e.g. a human).
  • a method of promoting diabetic ulcer healing comprising administering a therapeutically-effective amount of a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein) to a patient in need of such treatment.
  • nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA- 210 (i.e. the nucleic acids of the invention, as defined herein) for use in promoting diabetic ulcer healing.
  • nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 i.e. the nucleic acids of the invention, as defined herein
  • a method of promoting ulcer healing in a patient having diabetes comprising administering a therapeutically-effective amount of a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein) to a patient in need of such treatment.
  • nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein) for use in promoting ulcer healing in a patient having diabetes.
  • nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein) for the manufacture of a medicament for promoting ulcer healing in a patient having diabetes.
  • references to promoting diabetic ulcer healing and promoting ulcer healing in a patient having diabetes may both be understood to indicate improving the rate of healing of ulcers in patients having diabetes (i.e. diabetic ulcers) such that an increased number of patients heal within a certain time frame or the ulcer heals (i.e the skin or mucous membrane (e.g. skin) heals over) within an improved time frame relative to an untreated ulcer.
  • this time frame may be three months
  • ischemic diabetic ulcers the time frame may be six months.
  • promoting diabetic ulcer healing may comprise achieving a measurable decrease in the size (e.g.
  • the size of the ulcer may be reduced by at least 10%, for example at least 20%, such as at least 50% (e.g. at least 75%) following treatment with the nucleic acids of the invention.
  • diabetes may be understood to encompass type 1 diabetes, type 2 diabetes and less common subtypes such as gestational diabetes, maturity-onset diabetes in the young (MODY), latent autoimmune diabetes of adults (LADA), cystic fibrosis-related diabetes (CFRD) and the like.
  • MODY maturity-onset diabetes in the young
  • LADA latent autoimmune diabetes of adults
  • CRD cystic fibrosis-related diabetes
  • references to diabetes will refer to type 1 or type 2 diabetes.
  • ulcer may refer to an open lesion on an internal or external body surface caused by a break in the skin or mucous membrane, which is slow to heal and/or fails to heal. Ulcers can form on a range of body surfaces, such as in the mouth, in the gastrointestinal tract or on the skin.
  • the ulcer being treated with the nucleic acids of the invention occurs on the skin, such an ulcer may be referred to as a skin ulcer.
  • skin ulcers may be positioned anywhere on the body of the patient being treated.
  • the ulcer may be positioned on the leg or foot (e.g. the foot) of the patient being treated.
  • Such ulcers may be referred to as 'leg ulcer(s)' and 'foot ulcer(s)', respectively.
  • the ulcer is not an ischemic ulcer (i.e. the ulcer is a non-ischemic ulcer).
  • the ulcer Ulcers in patients suffering from diabetes may be referred to as diabetic ulcers.
  • the ulcer is a diabetic ulcer.
  • the ulcer is a diabetic leg ulcer or a diabetic foot ulcer (e.g. a diabetic foot ulcer).
  • the term (diabetic) leg ulcer may be understood to refer to an ulcer formed on the leg of an affected patient. Such an ulcer may form on the upper leg (e.g. in the groin and/or on the thigh), on/around the knee, and/or, more particularly on the lower leg (e.g. on the shin, the calf and/or on/around the ankle).
  • the term (diabetic) foot ulcer may be understood to refer to an ulcer formed on the foot of an affected patient. Such an ulcer may form on/around the ankle, on the top of the foot, on/around the heel, on the toes and/or, more particularly, on the bottom (i.e. the sole) of the foot.
  • ulcers formed on/around the ankle of an affected patient may fall under the definitions of both (diabetic) leg and foot ulcers.
  • Diabetic ulcers may be divided into different subtypes depending on the underlying condition responsible for their cause. Ulcers occurring in patients suffering from diabetes-induced peripheral neuropathy (preferably in the substantial absence of vascular disease) in the affected limb may be referred to as neuropathic diabetic ulcers, and ulcers occurring in patients suffering from vascular disease (e.g. diabetes-induced vascular disease) in the affected limb may be referred to as ischemic diabetic ulcers. Diabetic ulcers may also have mixed aetiology, and such ulcers may be referred to as neuroischemic ulcers.
  • the administration of the nucleic acids of the invention may provide an effective treatment for diabetic ulcers (e.g. diabetic skin ulcers) regardless of their aetiology.
  • the (diabetic) ulcer for example, the diabetic leg or foot ulcer (e.g. diabetic foot ulcer) is a neuropathic diabetic skin ulcer (for example, a neuropathic diabetic leg or foot ulcer (e.g. a neuropathic diabetic foot ulcer)).
  • the neuropathic diabetic ulcer for example, the neuropathic diabetic leg or foot ulcer (e.g. neuropathic diabetic foot ulcer)
  • the diabetic skin ulcer for example, the diabetic leg or foot ulcer (e.g. diabetic foot ulcer) is an ischemic diabetic skin ulcer (for example, an ischemic diabetic leg or foot ulcer (e.g. an ischemic diabetic foot ulcer)).
  • the diabetic skin ulcer for example, the diabetic leg or foot ulcer (e.g. diabetic foot ulcer)
  • a neuroischemic diabetic skin ulcer for example a neuroischemic diabetic leg or foot ulcer (e.g. a neuroischemic diabetic foot ulcer)
  • microRNA-210 may enhance the healing of diabetic ulcers by enhancing the response to hypoxia, which is impaired by the chronically high blood glucose levels experienced by diabetic patients.
  • hypoxia which is impaired by the chronically high blood glucose levels experienced by diabetic patients.
  • One aspect of the hypoxic response that is impaired under hyperglycaemic conditions is the proliferation and migration of fibroblasts, the cells responsible for the production of fibrous tissue such as collagen and the extracellular matrix.
  • a method of enhancing the hypoxic response in a diabetic ulcer comprising administering a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein) to a patient in need thereof.
  • enhancing the hypoxic response may refer to improving one or more processes mediated by hypoxia-inducible factor 1 (HIF-1) under hypoxic conditions.
  • HIF-1 hypoxia-inducible factor 1
  • an increase in angiogenesis, cell proliferation, cell survival, cell migration, erythropoiesis and cell differentiation e.g. fibroblast proliferation, migration and differentiation
  • recruitment of endothelial precursors cells antibacterial capacity.
  • a method of restoring fibroblast function e.g. proliferation and migration and/or synthesis of extracellular matrix and collagen
  • a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 i.e. the nucleic acids of the invention, as defined herein
  • a method of promoting the formation of extracellular matrix and/or collagen in dermal tissue in a diabetic ulcer comprising administering a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein) to a patient in need thereof.
  • a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 i.e. the nucleic acids of the invention, as defined herein
  • a key process in the final stages of ulcer healing is the re-epithelialization of the wound.
  • a method of promoting the re-epithelialization of a diabetic ulcer comprising administering a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA- 210 (i.e. the nucleic acids of the invention, as defined herein) to a patient in need thereof.
  • nucleic acids of the invention are useful as pharmaceuticals. Such nucleic acids may be administered alone or may be administered by way of known pharmaceutical compositions/formulations.
  • nucleic acids may be administered in the uses and methods of treatment, promoting healing, enhancing the hypoxic response, restoring fibroblast function, promoting the formation of extracellular matrix and/or collagen and promoting re-epithelialization defined herein (e.g. for the first to seventh aspects of the invention)
  • the nucleic acid of the invention as defined herein may be administered in the form of a pharmaceutical composition.
  • a pharmaceutical composition comprising a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein), and optionally one or more pharmaceutically acceptable adjuvant, diluent and/or carrier, for use in the treatments and methods defined herein (e.g. for the first to seventh aspects of the invention).
  • a method as defined herein e.g.
  • a pharmaceutical composition comprising a nucleic acid selected from the group consisting of mature microRNA-210 and precursors to mature microRNA-210 (i.e. the nucleic acids of the invention, as defined herein) and optionally one or more pharmaceutically-acceptable excipient to a patient in need thereof.
  • Pharmaceutically-acceptable excipients include vehicles, adjuvants, carriers, diluents, pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like.
  • nucleic acids of the invention may act locally (i.e. at the ulcer site). Therefore, the skilled person will understand that the nucleic acids and compositions as described for the first to eighth aspects of the invention may be administered topically in a pharmaceutically-acceptable dosage form. Suitable routes of administration may include direct administration to the skin (dermal) or mucous membrane surface, subcutaneous, intradermal or transdermal administration (e.g. via microneedle injection or transdermal patch).
  • Suitable dosage forms include, for example, liposomal systems (e.g. suspensions) and emulsions, and may be in the form of liquids, lotions, creams, ointments and/or aerosols.
  • Liquid preparations may be aqueous or oil based, and may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
  • various delivery systems may be used to transfer/introduce the nucleic acids of the invention into cells, such as encapsulation in liposomes, targeted liposomes, dendritic polyglycerolamine nanocarriers, nanoparticles, microparticles, microcapsules, electroporation, nucleofection, ultrasound based, laser based, recombinant cells that are capable of expressing microRNA-210, receptor- mediated endocytosis, construction of microRNA-210 as part of a viral vector or other vector, viral vectors that are capable of being reproduced without killing the cell during the process of reproduction, viral vectors that are not capable of reproduction, injection of cells that produce viral vectors that comprise the nucleic acids of the invention, injection of polynucleotides, electroporation, calcium phosphate mediated transfection, and the like, or any other methods known to the skilled person.
  • nucleic acids of the invention and compositions comprising the same may be administered (for example, as formulations as described hereinabove) at varying doses, with suitable doses being readily determined by one of skill in the art. Dosage and frequency of administration may be selected in relation to the pharmacological properties of the nucleic acids to be delivered (i.e. naked RNA, vectors, delivery particles used, and the like). In some embodiments, the nucleic acids of the invention (alone or in combination with other agents) may be administered in a dose having an amount of between about 0.01 mg and about 10 mg per administration/treatment per day.
  • the amount may be between about 0.01 mg and about 8 mg per administration/treatment, such as between about 0.01 mg and about 2 mg per administration/treatment, for instance, between about 0.05mg and about 4 mg per administration/treatment, particularly, between about 0.05 mg and about 2 mg per administration/treatment, more particularly, between about 0.08 mg and about 2 mg per administration/treatment (e.g. be between about 0.08 mg and about 1 mg per administration/treatment).
  • the amount may be between about 0.5 mg and about 9 mg per administration/treatment.
  • the nucleic acids of the invention may be formulated in a saline solution (such as PBS).
  • the doses disclosed herein may be administered at any administration regime, such as, 1 to 5 times a day, 1 to 10 times a week or 1 to 15 times a month, wherein such administration may be at identical or different time intervals and/or at the same or different time of day.
  • administration regime such as, 1 to 5 times a day, 1 to 10 times a week or 1 to 15 times a month, wherein such administration may be at identical or different time intervals and/or at the same or different time of day.
  • the term about when being used to refer to a numerical value may be understood in indicate a variation of ⁇ 10%, in particular ⁇ 5%, such as ⁇ 2% (e.g. ⁇ 1 %) of the stated value.
  • the nucleic acids of the invention may be introduced in any amount that allows delivery of at least one copy (i.e. of mature microRNA-210) per cell being treated.
  • At least 5 copies or at least 10 copies such as at least 100 copies or at least 500 copies (e.g. at least 1000 copies) may give an improved effect.
  • the skilled person e.g. the physician
  • the above-mentioned dosages are exemplary; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • nucleic acids and methods described herein may have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, and/or have other useful pharmacological properties over equivalent methods known in the art, whether for use in the above-stated indications or otherwise.
  • such methods may have the advantage that they significantly improve the healing outcomes for and thus the prognosis for patients suffering from diabetic ulcers.
  • Figure 1 illustrates the effect of the administration of a miR-210 mimic on wound healing in diabetic mice. A clear improvement in the rate of wound healing was observed for the miR-210 mimic compared to the negative control.
  • Figure 2 illustrates the effect of a miR-210 mimic on human fibroblast migration relative to a control.
  • the effect was investigated under normoxic conditions at normal glucose levels (N5), under hypoxic conditions at normal glucose levels (H5) and under hypoxic conditions at high glucose levels (H30). A clear increase relative to the control was observed under hypoxic conditions at high glucose levels.
  • Figure 3 illustrates the effect of a miR-210 mimic on human fibroblast proliferation relative to a control.
  • the effect was investigated under normoxic conditions at normal glucose levels (N5), under hypoxic conditions at normal glucose levels (H5) and under hypoxic conditions at high glucose levels (H30). A clear increase relative to the control was observed under hypoxic conditions at high glucose levels.
  • Example 1 The effect of the local injection of a microRNA-210 mimic on wound healing in diabetic mice
  • mice Twelve-week-old male diabetic (db/db) mice on the C57BI/6J background (Charles Rivers, Jackson Labs, USA) were used. All experimental groups were age-, weight- and blood glucose-matched. The mice were anesthetized with 3% isoflurane (Abbott). The hair on the backs of the mice was removed using a shaver followed by a depilatory cream. After cleansing the skin with alcohol, wounds were made on the dorsum using a 6-mm biopsy punch on each side of the midline. Mice received buprenorphine (0.03 mg/kg) twice a day to relieve any potential pain and distress for the first two days and were placed in single cages after wounding.
  • buprenorphine (0.03 mg/kg) twice a day to relieve any potential pain and distress for the first two days and were placed in single cages after wounding.
  • miRIDIAN miR-210 mimic (miRIDIAN mmu-miR-210-3p (based on the sequence MIMAT0000658 (CUGUGCGUGUGACAGCGGCUGA (SEQ ID NO: 1); Cat #: C-310570-05; Dharmacon) or negative control (miRIDIAN cel-miR-67 (based on the sequence MIMAT0000039 (UCACAACCUCCUAGAAAGAGUAGA (SEQ ID NO: 2); Cat #: CN-001000-01 ; Dharmacon) were injected along the edge of the wound intradermally. The injection was repeated 6 days after wounding. The wound biopsies and intact skin away from the injection site were taken after 12 days.
  • Transfection of miR-210 mimic in HDF cells Human dermal fibroblast (HDF) cells were seeded with 80-90% confluency on the first day. Next day, 1 , 10 and 20nM miR-210 mimic (miRIDIAN mmu-miR-210-3p; Cat #: C-310570- 05; Dharmacon) or negative control (miRIDIAN cel-miR-67; Cat #: CN-001000-01; Dharmacon) were transfected using RNAiMAX transfection reagent (Thermo Fisher Scientific, Cat # 13778075). The cells were allowed to recover for 48 hours before performing the analyses.
  • HDF Human dermal fibroblast
  • HDF cells were seeded and transfected in 24 wells. After 48 hours, scratches were made and the cells were exposed to normal (5.5mM) or high glucose (30mM) in normoxia (21 %) or hypoxia (1 %). Cells were serum starved and mitomycin-C (10ug/ml_, Roche, Cat # 10107409001) was added to abolish the effects of proliferation. The migration was calculated from the area free of cells at 0 hours and 24 hours. As can be seen from Figure 2, the microRNA-210 mimic increased fibroblast migration significantly under hypoxic and high glucose conditions.
  • Example 3 The effect of a microRNA-210 mimic on fibroblast proliferation under normal and high glucose and hypoxic and normoxic conditions Transfection of miR-210 mimic in HDF cells
  • HDF Human dermal fibroblast
  • HDF cells were starved for 24 hours and exposed to normal (5.5mM) or high glucose in normoxia (21 %) or hypoxia (1 %) for 24 hours.
  • the cell proliferation was measured using the BrdU Cell Proliferation ELISA kit (Abeam, ab-126556). As can be seen from Figure 3, the microRNA-210 mimic increased fibroblast proliferation significantly under hypoxic and high glucose conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/GB2017/050923 2017-03-31 2017-03-31 Methods of treatment of diabetic ulcers with microrna WO2018178608A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/GB2017/050923 WO2018178608A1 (en) 2017-03-31 2017-03-31 Methods of treatment of diabetic ulcers with microrna
CN201780089103.1A CN110494146A (zh) 2017-03-31 2017-03-31 用微小rna治疗糖尿病溃疡的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2017/050923 WO2018178608A1 (en) 2017-03-31 2017-03-31 Methods of treatment of diabetic ulcers with microrna

Publications (1)

Publication Number Publication Date
WO2018178608A1 true WO2018178608A1 (en) 2018-10-04

Family

ID=58640915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2017/050923 WO2018178608A1 (en) 2017-03-31 2017-03-31 Methods of treatment of diabetic ulcers with microrna

Country Status (2)

Country Link
CN (1) CN110494146A (zh)
WO (1) WO2018178608A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114028413A (zh) * 2021-12-17 2022-02-11 广州市麦施缔医疗科技有限公司 人体has-mir-200b-3p在制备急慢性创面药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020307A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
WO2016054399A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Enhancing dermal wound healing by downregulating microrna-26a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020307A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
WO2016054399A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Enhancing dermal wound healing by downregulating microrna-26a

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GREEN; SAMBROOK: "Molecular Cloning: A Laboratory Manual", 2012, COLDSPRING HARBOUR LABORATORY PRESS
MOHAMAD AMER ALAITI ET AL: "Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 16, no. 10, 26 September 2012 (2012-09-26), RO, pages 2413 - 2421, XP055375927, ISSN: 1582-1838, DOI: 10.1111/j.1582-4934.2012.01557.x *
R MADHYASTHA ET AL: "MicroRNA signature in diabetic wound healing: promotive role of miR-21 in fibroblast migration", INTERNATIONAL WOUND JOURNAL, vol. 9, no. 4, 9 August 2012 (2012-08-09), UK, pages 355 - 361, XP055375912, ISSN: 1742-4801, DOI: 10.1111/j.1742-481X.2011.00890.x *
ZHAO MING ET AL: "Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4+T cells of psoriasis vulgaris", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 150, no. 1, 5 December 2013 (2013-12-05), pages 22 - 30, XP028671357, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2013.10.009 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114028413A (zh) * 2021-12-17 2022-02-11 广州市麦施缔医疗科技有限公司 人体has-mir-200b-3p在制备急慢性创面药物中的应用

Also Published As

Publication number Publication date
CN110494146A (zh) 2019-11-22

Similar Documents

Publication Publication Date Title
US8906875B2 (en) Methods of treating vascular inflammatory disorders
JP2011508605A (ja) 創傷治癒組成物および治療
CN110564842B (zh) 细胞色素酶cyp26a1在制备治疗神经病理性疼痛的药物中的应用
Fukuta et al. Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF-κB decoy oligodeoxynucleotide
Chen et al. Anti‑inflammatory effects of miR‑150 are associated with the downregulation of STAT1 in macrophages following lipopolysaccharide treatment
WO2018178608A1 (en) Methods of treatment of diabetic ulcers with microrna
JP7032140B2 (ja) 嚢胞性線維症の処置のための方法及び医薬組成物
US20220249511A1 (en) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
US8247389B2 (en) Treatment of scleroderma
CN109234381B (zh) miR-2682-5p作为肾纤维化标志物的应用
US20210079100A1 (en) Methods and compositions for treating hyperpigmentation disorders
Li et al. Decrypting the circular RNAs does a favor for us: Understanding, diagnosing and treating diabetes mellitus and its complications
US20170166897A1 (en) Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
US10443059B2 (en) Pharmaceutical composition and method for reducing scar formation
TWI824901B (zh) miR-200b在促進糖尿病傷口癒合上的用途
CN111249300B (zh) 褪黑素联合甲钴胺在治疗糖尿病创面愈合障碍中的应用
TW201335173A (zh) 一種用以抑制nmda受體nr1之微小rna、一種微小rna用以製備抑制疼痛藥物之用途、以及一種減緩皮膚炎症性疼痛之醫藥組合物
TWI542352B (zh) 一種用以減少疤痕形成的醫藥組合物
US10113170B2 (en) Preventing and treating inflammatory skin diseases
Lee et al. Therapeutic potential of human stem cell-derived extracellular vesicles in idiopathic pulmonary fibrosis
WO2024112653A1 (en) Inhibitory nucleic acids and methods of use thereof
KR20160038190A (ko) 마이크로rna-192에 대한 길항제를 포함하는 간 섬유화 억제용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17720205

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17720205

Country of ref document: EP

Kind code of ref document: A1